Dive Into Dollar Tr...
Health Care: Drugs
Zalicus Inc. (ZLCS: NASDAQ)
$0.60 -0.02 | -3.23%
05/17/13 - 03:58 PM ET
710.37K / 595.50K
Vol / Avg. Vol:0.63 / 0.62
Open / Prev. Close:0.60 - 0.63
Today's Range:0.43 - 1.62
52 Wk Range:-4.62%
Performance YTD:TheStreet Rating:
Portfolios with ZLCS
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- UserBiotech88
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- UserTrack1
- ContributorStocks Under-$10 Setting Up...
- User0730
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Setting Up...
Latest ZLCS Headlines from TheStreet
- 5 Stocks Under $10 Set to Soar Higher 01.31.13 | 01:01 pm
- Acadia Pharma Selling Stock Ahead of Key Study Results 11.06.12 | 12:11 pm
- 8 Stocks Under $10 Making Big Moves 08.30.12 | 02:08 pm
- 5 Stocks Poised for Breakouts 08.10.12 | 01:08 pm
- 5 Stocks Under $10 Set to Soar 07.26.12 | 12:07 pm
- Horizon Pharma: Rayos FDA Approval Thursday Seems Likely 07.25.12 | 10:07 am
- Biotech Stock Mailbag: Zalicus, Amarin 07.13.12 | 06:07 am
- 7 Stocks Under $10 Streaking Higher 06.07.12 | 04:06 pm
- 22 Biopharma Stocks With Breakout Potential in 2012 05.22.12 | 08:05 am
- 8 Stocks Under $10 Moving Higher 03.20.12 | 12:03 pm
Press Releases for ZLCS
- Zalicus Presents Data Demonstrating Advantages Of State-Dependent Ion Channel Screening - Business Wire 03.19.13 | 08:03 am
- Zalicus Reports Financial Results For The Fourth Quarter And Year End 2012 - Business Wire 03.06.13 | 07:03 am
- Zalicus Granted Composition-of-Matter Patent For Z944 - Business Wire 02.20.13 | 08:02 am
- Zalicus To Present At The 2013 BIO CEO & Investor Conference - Business Wire 02.05.13 | 08:02 am
- Zalicus Initiates The Second Of Two Phase 2a Studies With Z160 - Business Wire 01.03.13 | 07:01 am
- Zalicus To Present At The Oppenheimer 23rd Annual Healthcare Conference - Business Wire 12.05.12 | 04:12 pm
- Zalicus’ Z160 For Chronic Neuropathic Pain Selected As A Top 10 Project To Watch - Business Wire 11.27.12 | 08:11 am
- Zalicus Reports Financial Results For The Third Quarter 2012 - Business Wire 11.08.12 | 07:11 am
- Zalicus Licensee, Sanofi, Provides Status Update On Prednisporin (FOV1101) - Business Wire 10.25.12 | 07:10 am
- Zalicus Reports Top Line Phase 2b Trial Results With Synavive In Rheumatoid Arthritis - Business Wire 09.10.12 | 08:09 am
Partner Headlines for ZLCS
- A Study Of 3 Biotechs - A Story Of Hope, Potential And Partnerships - Seeking Alpha 03.18.13 | 09:03 am
- Under Construction Rehash: Buy Acadia And Astex - Seeking Alpha 09.20.12 | 09:09 am
- UPDATE: Rodman & Renshaw Downgrades Zalicus to Market Perform on Synavive Failure - Benzinga 09.11.12 | 01:09 pm
- Morning Market Losers - Benzinga 09.10.12 | 09:09 am
- Buy Zalicus For A 120% Upside - Seeking Alpha 09.05.12 | 09:09 am
- Investing in Biotech Stocks? The Journey to Profits Requires a Good GPS - NASDAQ 08.31.12 | 04:08 pm
- Zalicus: When Push Comes To Shove - Seeking Alpha 08.31.12 | 09:08 am
- Why Zalicus Buyers See $3 Again - Seeking Alpha 08.08.12 | 09:08 am
- 3 Rising Biotech Stars All Under $2/Share - Seeking Alpha 06.18.12 | 09:06 am
- Look For These 5 Biotech Stocks Heading North - Seeking Alpha 06.07.12 | 09:06 am
